Skip to main content

Advertisement

Table 1 Clinical characteristics of the studied patients

From: Near-infrared spectroscopy StO2 monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock

  Treated (n = 32) Controls (n = 26) p
Gender (male %) 63% 50% 0.3
Age (yr) 63 ± 15 73 ± 12 0.02
Origin of sepsis    
Abdominal 56% 42%  
Bone 0% 4%  
Respiratory 34% 27%  
Skin/soft tissue 10% 23%  
Urinary tract 0% 4%  
SAPS II 56 ± 13 59 ± 11 0.4
APACHE II 25 ± 6 24 ± 7 0.6
SOFA score at inclusion 11 ± 3 11 ± 2 0.4
Value at inclusion Mean arterial pressure (mmHg) 77 ± 9 75 ± 11 0.6
  Norepinephrine dose (mcg/kg/min) 0.8 ± 1.0 0.4 ± 0.33 0.04
  Heart rate (bpm) 94 ± 20 96 ± 22 0.7
  Lactate (mmol/L) 3.5 ± 2.0 4.0 ± 3.5 0.6
  pH 7.30 ± 0.11 7.31 ± 0.12 0.8
  Base deficit (mmol/L) −9.0 ± 4.3 −7.5 ± 7.2 0.4
  ScvO2 (%) 70 ± 10 71 ± 13 0.8
  SpO2 (%) 96 ± 4 98 ± 3 0.2
  PaO2/FiO2 181 ± 102 255 ± 164 0.3
  Hb (g/dL) 11.2 ± 2.0 10.9 ± 2.2 0.6
  StO2 (%) 80 ± 8 78 ± 12 0.5
  Deoxygenation slope (%/min) −16.2 ± 18 −17.4 ± 14.4 0.4
  Reoxygenation slope (%/s) 3.2 ± 2.6 2.3 ± 1.8 0.1
Mortality (n, %) 6 (19) 10 (38) 0.09
Length of ICU stay (days) 26 ± 21 19 ± 17 0.2
  1. Clinical characteristics at inclusion according to treatment group. Continuous variables are expressed as mean ± SD. Categorical variables are expressed as proportions (%). Two-tailed significance is shown under “p” column.